Market Highlights from BCC Research
Gut Microbiome Predicts Response to IBD Therapy
The microbial population in a patient’s gut may predict how they will respond to treatment for Crohn’s disease and other inflammatory bowel diseases (IBDs). A research team from Massachusetts General Hospital (MGH), the Broad Institute of MIT, and Harvard University concluded there were commonalities in the microbiomes of people with IBD for whom antibody-based treatments were successful. Their findings were published last month in Cell Host & Microbe.
Gut Microbiome Predicts Response to Cancer Immunotherapy
Global Market for Human Microbiome–Based Drugs by Region, 2018–2024
The human microbiome–based drugs and diagnostics sector is set to develop and grow, primarily driven by three factors: (1) proof-of-concept data from a wide range of microbiome projects in multiple diseases with substantial unmet needs, (2) increasing collaboration activity between industry and academia to generate data on existing and new therapeutic targets, and (3) continued investment by both private and public sector players.
As is the case for many emerging technologies, microbiome-based companies and medical treatments will have to navigate regulatory controls and other developments. Frameworks, such as clinical trial standards, protections for intellectual property, and ownership rules, will develop both nationally and worldwide. And, definitions are still evolving for different bacteria—some are live, whereas others are engineered—as well as the rules for donors and recipients of bacteria or small molecules.
The human microbiome–based drugs and diagnostics market represents a multibillion-dollar opportunity. Small start-up companies spearheading the development of this sector are expected to further build on their collaborations with big pharmaceutical companies that have the capabilities and commercial infrastructure to build on the science and transform it into real business.